Otsuka Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Second Quarter of Fiscal Year Ending December 31, 2022; Provides Earnings Guidance for the Year Ending December 31, 2022
May 13, 2022 at 12:30 am EDT
Share
Otsuka Holdings Co., Ltd. provided consolidated earnings guidance for the second quarter of fiscal year ending December 31, 2022. For the period, the company expects revenue of JPY 767,000 million, Business profit of JPY 111,000 million, operating profit of JPY 112,500 million, profit for the year of JPY 87,500 million or JPY 158.55 per share.
For the year ending December 31, 2022, the company expects revenue of JPY 1,550,000 million, Business profit of JPY 190,000 million, operating profit of JPY 192,000 million, profit for the year of JPY 149,000 million or JPY 269.17 per share.
Otsuka Holdings Co, Ltd. is a holding company organised around 4 areas of activity:
- manufacture and sale of pharmaceutical products (65.2% of sales): prescription drugs and intravenous solutions mainly for the treatment of central nervous system disorders, cancer, cardiovascular, gastrointestinal and ophthalmic diseases. In addition, the group sells diagnostic products and medical devices;
- manufacture and sale of nutraceutical products (25.1%): functional foods and beverages, OTC products, nutritional supplements;
- production of mineral waters, beverages and foods (2.1%);
- other (7.5%): manufacture of functional chemicals and fine chemicals, provision of logistics services, manufacture of electronic products, etc.
Net sales by source of income are divided between sales of products (93.8%), sales of licences and royalties (1.8%) and other (4.4%).
Net sales are distributed geographically as follows: Japan (43.2%), North America (34%),
Otsuka Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Second Quarter of Fiscal Year Ending December 31, 2022; Provides Earnings Guidance for the Year Ending December 31, 2022
OTSUKA HOLDINGS CO., LTD. 
